Article
Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre-and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir.
Antiviral therapy - 1 Jan 2018
McPhee Fiona, Hernandez Dennis, Zhou Nannan, Ueland Joseph, Yu Fei, Vellucci Vincent, Huang Xin, Wang Xuning, Ishikawa Hiroki, Karino Yoshiyasu, Kumada Hiromitsu
Abstract excerpt
BACKGROUND: Daclatasvir (DCV; non-structural [NS]5A inhibitor) plus asunaprevir (ASV; NS3 inhibitor) plus beclabuvir (BCV; non-nucleoside NS5B inhibitor) is an approved regimen for hepatitis C virus (HCV) genotype (GT)-1 treatment in Japan. A comprehensive analysis of pre-treatment and treatment-emergent HCV resistance to this regimen ± ribavirin (RBV) was performed. METHODS: Data were pooled from five Phase 2/3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.